Enovis Corporation

Enovis Corporation

ENOVNYSE / NASDAQHealthcareSmall cap

$25.47-$0.76 (-2.9%)

Last close · Data as of Nov 20, 2026

Market cap
$1.3B
P/E
-1.1x
EV / EBITDA
-3.2x
Revenue
$2.2B
Net margin
-52.7%
ROCE
-0.6%

-5.1% over the last year

Enovis Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+23.1%
3M
-2.7%
6M
-3.7%
1Y
-5.1%
5Y
-70.7%

52-week range

Day change -$0.76 (-2.9%) from $26 to $25 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ENOV, bought on each weekday since 2021.

News & filings

What Enovis filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 1.2 billion US dollars in fiscal 2025.

Strengths (1)

  • EBITDA grew 72.6% in fiscal 2025, 65.9 points more than revenue.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments.

Read moreShow less

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

Sector
Healthcare
Shares outstanding
57.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.3B
P/E
-1.1x
P/B
0.9x
EV / EBITDA
-3.2x
EV / Sales
1.2x
P/S
0.6x
52-week high
$31.42
52-week low
$17.43

Profitability

Operating margin
-0.8%
Net margin
-52.7%
EBITDA margin
-36.9%
ROE
-79.5%
ROCE
-0.6%
ROA
-30.9%
Asset turnover
0.59

Growth

Revenue
$2.2B
Revenue growth, 1Y
6.7%
Revenue CAGR, 3Y
12.9%
Net profit growth, 1Y
43.5%
Free cash flow
$19.9M

Solvency

Current ratio
2.02
Debt / Equity
0.93
Debt / Assets
0.36
CFO / Net profit
-0.18
Cash / Market cap
2.8%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$2.2B
Cost of revenue$902.8M
Gross profit$1.3B
Operating expenses$1.4B
Research and development$120.3M
Selling, general and administrative$1.1B
Operating income-$18.9M
Interest and other-$1.1B
Pretax income-$1.2B
Tax and other$25.0M
Net income-$1.2B

Revenue and net profit

Revenue grew 6.7% in FY2025; net profit is the dashed line.

Enovis Corporation revenue and net profit by fiscal year
Enovis Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$1.6B-$13.3M
FY2023$1.7B-$33.3M
FY2024$2.1B-$825.5M
FY2025$2.2B-$1.2B

Cash flows

FY2025: $217.3M from operations, $19.9M free after investment (dashed).

Enovis Corporation operating and free cash flow by fiscal year
Enovis Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$55.9M-$161.3M
FY2023$135.0M$12.8M
FY2024$113.5M-$67.2M
FY2025$217.3M$19.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$2.2B+6.7%1Y
EBITDA
-$830.2M
Net profit
-$1.2B
Cash from operations
$217.3M+91.4%1Y
Free cash flow
$19.9M
Revenue CAGR, 3Y
12.9%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$2.2B-$830.2M-$1.2B$19.9M-79.5%+6.7%+43.5%

Monthly returns

Month-by-month returns of ENOV across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$3.8B
Liabilities$2.3B
Equity$1.5B
Paid-in capital$3.0B
Retained earnings-$1.5B
Minority interest$2.3M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ENOV highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. Enovis Corporation (this company)1.2x

Not shown (no positive earnings and no EV / Sales): Bicara Therapeutics Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Enovis CorporationENOVthis company$1.3B-1.1x0.9x-79.5%-3.2x
Bicara Therapeutics Inc.BCAX$1.3B-9.7x3.3x-34.4%-8.0x
Inhibrx Biosciences, Inc.INBX$1.3B-9.6x167.5x-1752.2%-10.5x
Ardelyx, Inc.ARDX$1.3B-21.7x8.0x-36.9%-50.5x
Tandem Diabetes Care, Inc.TNDM$1.3B-6.5x8.6x-131.9%-9.6x
AdaptHealth Corp.AHCO$1.3B-18.7x0.9x-4.7%6.6x
BioLife Solutions, Inc.BLFS$1.3B-288.0x3.6x-1.2%-109.8x
Teladoc Health, Inc.TDOC$1.3B-6.6x1.0x-14.5%9.8x
Harrow, Inc.HROW$1.3B-251.6x24.7x-9.8%34.6x
Peer median—-14.2x5.8x-24.4%-8.8x

Year-to-date ROI

ENOV since 1 January, against earlier years.

Historical volatility

ENOV's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Enovis Corporation operating margin by fiscal year
Enovis Corporation operating margin by fiscal year
DateOperating margin
FY2022-5.8%
FY2023-2.8%
FY2024-4.9%
FY2025-0.8%
LineFY2025
Cost of revenueCost Of Revenue$902.8M
Gross profitGross Profit$1.3B
Operating expensesOperating Expense$1.4B
Research and developmentResearch And Development$120.3M
Selling, general and administrativeSelling General And Administration$1.1B
Depreciation and amortisationDepreciation And Amortization In Income Statement$173.7M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$173.7M
Amortization$173.7M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$173.7M
Total expensesTotal Expenses$2.3B
Pretax incomePretax Income-$1.2B

Learn while you research

Academy chapters picked for Enovis Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →